Form 4: Stoke Therapeutics CMO Vests 33,850 Shares

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the vesting and acquisition of 33,850 shares of common stock through Restricted Stock Units.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), acquired a total of 33,850 shares of common stock on March 15, 2026.
• These shares were acquired through the vesting and conversion of Restricted Stock Units (RSUs) at a price of $0 per share.
• The acquisitions consisted of 13,100 shares, 10,000 shares, and 10,750 shares from three separate RSU awards.
• Following these transactions, Barry Ticho directly beneficially owns 53,648 shares of Stoke Therapeutics common stock.
• Additionally, Barry Ticho continues to beneficially own 65,350 unvested Restricted Stock Units, comprising 13,100, 20,000, and 32,250 units from the respective awards.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and positive event, indicating continued insider ownership and alignment with shareholder interests, typical for executive compensation. It does not signal any new fundamental changes to the company's outlook.

Positives

• The acquisition of shares by a key executive increases insider ownership, aligning management's interests with those of shareholders.
• The vesting of RSUs is a standard component of executive compensation, indicating continued retention and incentivization of the Chief Medical Officer.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the vesting of equity awards like Restricted Stock Units, are a routine and expected part of executive compensation structures within the biotechnology industry. These mechanisms are designed to align the long-term interests of management with those of shareholders, fostering retention and incentivizing performance.

Comparison to Industry Standards

• StockSavvy.ai observes that equity-based compensation, such as RSUs with multi-year vesting schedules, is a standard practice across the biotechnology sector, comparable to compensation structures at companies like Biogen or Moderna.
• This approach is widely adopted to attract and retain high-caliber talent in a competitive industry, linking executive rewards directly to company performance and stock appreciation over time.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through greater insider ownership.
• Employees: Reinforces the company's commitment to equity-based compensation as a retention and incentive tool for key personnel.

Next Steps

• Future annual vesting events for the remaining 65,350 Restricted Stock Units held by Barry Ticho, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of Restricted Stock Units for a key executive. While it increases insider ownership, it does not provide new fundamental information about the company's operational performance or strategic direction to warrant a change in investment recommendation. It's a standard compensation event that does not alter the underlying investment thesis for Stoke Therapeutics.

Keywords

Stoke Therapeutics, STOK, Barry Ticho, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Common Stock, Chief Medical Officer, Equity Compensation